Development of therapeutic antibodies for the treatment of diseases

抗体 生物制药 单克隆抗体 双特异性抗体 药物开发 抗体-药物偶联物 嵌合抗原受体 医学 免疫学 免疫疗法 药品 免疫系统 生物 药理学 生物技术
作者
Zeng Wang,Guoqing Wang,Huaqing Lu,Hongjian Li,Mei Tang,Aiping Tong
出处
期刊:Molecular biomedicine [Springer Nature]
卷期号:3 (1): 35-35 被引量:157
标识
DOI:10.1186/s43556-022-00100-4
摘要

Since the first monoclonal antibody drug, muromonab-CD3, was approved for marketing in 1986, 165 antibody drugs have been approved or are under regulatory review worldwide. With the approval of new drugs for treating a wide range of diseases, including cancer and autoimmune and metabolic disorders, the therapeutic antibody drug market has experienced explosive growth. Monoclonal antibodies have been sought after by many biopharmaceutical companies and scientific research institutes due to their high specificity, strong targeting abilities, low toxicity, side effects, and high development success rate. The related industries and markets are growing rapidly, and therapeutic antibodies are one of the most important research and development areas in the field of biology and medicine. In recent years, great progress has been made in the key technologies and theoretical innovations provided by therapeutic antibodies, including antibody-drug conjugates, antibody-conjugated nuclides, bispecific antibodies, nanobodies, and other antibody analogs. Additionally, therapeutic antibodies can be combined with technologies used in other fields to create new cross-fields, such as chimeric antigen receptor T cells (CAR-T), CAR-natural killer cells (CAR-NK), and other cell therapy. This review summarizes the latest approved or in regulatory review therapeutic antibodies that have been approved or that are under regulatory review worldwide, as well as clinical research on these approaches and their development, and outlines antibody discovery strategies that have emerged during the development of therapeutic antibodies, such as hybridoma technology, phage display, preparation of fully human antibody from transgenic mice, single B-cell antibody technology, and artificial intelligence-assisted antibody discovery.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
打工人发布了新的文献求助10
刚刚
刚刚
1秒前
青黛发布了新的文献求助10
1秒前
奶味蓝完成签到,获得积分10
1秒前
研友_VZG7GZ的应助被风笛采纳,获得10
2秒前
薛禾完成签到,获得积分10
2秒前
xie发布了新的文献求助10
2秒前
陈树人完成签到,获得积分10
3秒前
占曼荷发布了新的文献求助10
3秒前
谢文轩完成签到,获得积分10
3秒前
4秒前
4秒前
wangs发布了新的文献求助10
4秒前
小fool完成签到,获得积分10
5秒前
DW的应助被ZM采纳,获得10
5秒前
yize发布了新的文献求助10
5秒前
彭于晏的应助被yj采纳,获得10
5秒前
DoctorG发布了新的文献求助10
5秒前
坦率的映萱完成签到,获得积分10
6秒前
faye完成签到,获得积分10
6秒前
6秒前
工作热情仔的应助被棠漓采纳,获得50
6秒前
blackbird007发布了新的文献求助20
6秒前
6秒前
liuyc完成签到 ,获得积分10
7秒前
小壳儿完成签到 ,获得积分10
7秒前
朴素新儿完成签到,获得积分10
7秒前
D.lon完成签到,获得积分10
7秒前
7秒前
8秒前
闪闪的映波完成签到,获得积分10
8秒前
拼搏半梦完成签到,获得积分10
8秒前
9秒前
玻璃雨趣发布了新的文献求助10
9秒前
9秒前
11秒前
江南脆饼完成签到,获得积分10
11秒前
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181279
求助须知:如何正确求助?哪些是违规求助? 9571198
关于积分的说明 21817073
捐赠科研通 7777612
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479519